 |
brentuximab vedotin |
|---|---|
| Trade Name | Adcetris(R) |
| Orphan Indication | Patients with diffuse large B-cell lymphoma |
| USA Market Approval | USA |
| USA Designation Date | 2014-01-31 00:00:00 |
| Sponsor | Seattle Genetics, Inc.;21823 30th Drive Southeast;Bothell, Washington, 98021 |
